Latest Articles

Publication Date
Catamenial Pneumothorax as an Underrecognized Manifestation of Thoracic Endometriosis: A 25-Year Single-Center Experience.

Objectives: Catamenial pneumothorax (CP) is a rare but clinically relevant cause of spontaneous pneumothorax (SP) in women and is associated with high recurrence rates. We hypothesized that CP is underrecognized …

Published: June 25, 2026, midnight
Comparative study of quality of life between endometriosis patients receiving GnRH agonist and dienogest therapy: A cross-sectional study using Endometriosis Health Profile-30 (EHP-30).

Endometriosis is a chronic gynecological disease that substantially impairs quality of life. Gonadotropin-releasing hormone (GnRH) agonists and dienogest are commonly used hormonal therapies for endometriosis; however, direct comparisons of their …

Published: June 25, 2026, midnight
4 chilling details about the Taylor Parker case missing from “Maternal Instinct” - Yahoo

4 chilling details about the Taylor Parker case missing from “Maternal Instinct” Yahoo

Published: June 24, 2026, 10:31 p.m.
Exclusive BAC Article: Absci Corporation; Positive Phase 1 Data ABS-201 AGA, Interim And Final POC Data 2nd Half 2026/Early 2027, Respectively, Advancement Endometriosis And Catalysts (NASDAQ:ABSI) - Seeking Alpha

Exclusive BAC Article: Absci Corporation; Positive Phase 1 Data ABS-201 AGA, Interim And Final POC Data 2nd Half 2026/Early 2027, Respectively, Advancement Endometriosis And Catalysts (NASDAQ:ABSI) Seeking Alpha

Published: June 24, 2026, 7:18 p.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com

Published: June 24, 2026, 11:25 a.m.
Absci stock surges 24% on positive Phase 1 hair loss drug data - Investing.com South Africa

Absci stock surges 24% on positive Phase 1 hair loss drug data Investing.com South Africa

Published: June 24, 2026, 11:14 a.m.
Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com - Investing.com India

Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com Investing.com India

Published: June 24, 2026, 11:13 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times

Published: June 24, 2026, 10:48 a.m.
Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart - Minichart

Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart Minichart

Published: June 24, 2026, 10:45 a.m.
Taking the combined oral contraceptive pill can increase binge eating, study suggests - MSN

Taking the combined oral contraceptive pill can increase binge eating, study suggests MSN

Published: June 24, 2026, 10:43 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!